CHEK2 and prostate cancer: Southey et al. (35) showed evidence of the relationship of this VUS (CHEK2 c.1312G>T) with risk of prostate cancer, with OR 2.21 (95% CI 1.06 to 4.63, p = 0.030), in European men.